1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (815) 227-2630.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening
Article first published online: 11 SEP 2006
DOI: 10.1002/cncr.22202
Copyright © 2006 American Cancer Society
Additional Information
How to Cite
Hoskins, K. F., Zwaagstra, A. and Ranz, M. (2006), Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer, 107: 1769–1776. doi: 10.1002/cncr.22202
Publication History
- Issue published online: 3 OCT 2006
- Article first published online: 11 SEP 2006
- Manuscript Accepted: 16 JUL 2006
- Manuscript Revised: 7 JUL 2006
- Manuscript Received: 10 MAY 2006
Funded by
- OSF Saint Anthony Foundation
REFERENCES
- 1, , . Assessing the risk of breast cancer. N Engl J Med. 2000; 342: 564–571.
- 2, , , et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol. 2003; 21: 593–601.
- 3, , , et al. Cancer risk prediction models: a workshop on development, evaluation and application. J Natl Cancer Inst. 2005; 97: 715–723.
- 4, , , et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879–1886.
- 5, , . Autosomal dominant inheritance of early onset breast cancer. Cancer. 1994; 73: 643–651.Direct Link:
- 6, , , et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66–71.
- 7, , , et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378: 789–792.
- 8, , . Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995; 57: 1457–1462.
- 9, , . Genetic epidemiology of breast and ovarian cancer. Epidemiol Rev. 1997; 19: 69–79.
- 10, , , et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676–689.
- 11, , , et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117–1130.
- 12Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet. 1994; 55: i–iv.
- 13Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol. 1996; 14: 1730–1736.
- 14U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005; 143: 355–361.
- 15, , , et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998; 90: 1371–1388.
- 16IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomized prevention trial. Lancet. 2002; 360: 817–824.
- 17, , , et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. 2002; 94: 160–165.
- 18, , , et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene and aromatase inhibition. J Clin Oncol. 2002; 20: 3328–3343.
- 19U.S. Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002; 137: 56–58.
- 20, , , et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999; 340: 77–84.
- 21, , , et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93: 1633–1637.
- 22, , , et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345: 159–164.
- 23, , , et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002; 346: 1616–1622.
- 24, , , et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346: 1609–1615.
- 25, , , et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography and clinical breast exam. JAMA. 2004; 292: 1317–1325.
- 26, , , et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351: 427–437.
- 27. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial: a reflective commentary. J Clin Oncol. 1999; 17: 1632–1639.
- 28, , , et al. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95: 526–532.
- 29, , , et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2.Cancer Genetics Studies Consortium. JAMA. 1997; 277: 997–1003.
- 30, , , et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994; 86: 620–625.
- 31, , , et al. Validation studies for model projecting the risk of invasive breast and total breast cancer incidence. J Natl Cancer Inst. 1999; 91: 1541–1548.
- 32, , , et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001; 93: 358–366.
- 33, , , et al. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J. 2002; 8: 23–27.Direct Link:
- 34, , , et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20: 1480–1490.
- 35, , , et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997; 336: 1409–1415.
- 36, , . Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62: 145–158.
- 37, , , et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004; 41: 474–480.
- 38, , . A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet. 2000; 58: 299–308.Direct Link:
- 39, , , et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996; 13: 123–125.
- 40, , , et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997; 60: 313–319.
- 41, , , et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336: 1401–1408.
- 42, , , et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996; 14: 185–187.
- 43, , , et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996; 13: 126–128.
- 44, , . Comparing the area under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837–845.
- 45, , . A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004; 23: 1111–1130.Direct Link:
- 46, , , et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002; 86: 76–83.